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ARTICLE
Effect of age at puberty on risk of multiple
sclerosis
A mendelian randomization study
Adil Harroud, MD, John A. Morris, BSc, Vincenzo Forgetta, PhD, Ruth Mitchell, PhD, George Davey Smith, DSc,







To investigate the potential for a causal effect of age at puberty on multiple sclerosis (MS)
susceptibility using a mendelian randomization (MR) approach.
Methods
We used 372 genetic variants strongly associated with age at menarche in a genome-wide
association study (GWAS) involving 329,245 women. The genetic architecture of pubertal
timing across both sexes is highly correlated (genetic correlation [rg] = 0.75, p = 1.2 × 10
−79),
allowing these variants to provide reliable insight into pubertal timing in males as well. The
effect of pubertal timing on risk of MS was measured with summary statistics from a GWAS of
14,802 cases with MS and 26,703 controls from the International Multiple Sclerosis Genetics
Consortium. Multivariable MR controlling for effects of body mass index (BMI) using genetic
data from additional consortia investigated whether pubertal effects on MS were dependent on
weight status.
Results
A 1-year increase in genetically predicted age at puberty decreased odds of MS by 8% (odds
ratio [OR] 0.92, 95% confidence interval [CI] 0.86–0.99, p = 0.03). However, multivariableMR
analysis showed that after accounting for effects on adult BMI, the association of age at puberty
with MS susceptibility attenuated (OR 0.96, 95% CI 0.88–1.04, p = 0.36). Similar results were
obtained when childhood BMI was incorporated. Sensitivity analyses provided no evidence of
major bias from genetic pleiotropy.
Conclusions
We found support for an association between higher age at puberty and decreased risk of MS
with a magnitude comparable to that reported in observational studies. This effect appears to be
largely mediated by the strong association between age at puberty and obesity. A large causal
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Epidemiologic studies have reported an increased risk of
multiple sclerosis (MS) with earlier age at puberty, particu-
larly among women.1–4 However, others failed to replicate
this finding.5–8 Pubertal timing has complex interactions with
weight status, whereby higher childhood adiposity leads to
earlier puberty, which in turn is associated with higher adult
bodymass index (BMI).9 Because evidence supports a role for
increased BMI in MS pathogenesis,10,11 at least part of the
observed link between pubertal timing and MS might be
explained by BMI.
Establishing a causal contribution of pubertal timing in MS is
crucial to understanding the effects of sex hormone exposure
and sexual maturation on disease etiology. This in turn may
lead to novel preventive or therapeutic strategies. It may also
clarify how the decreasing age at puberty over the past dec-
ades12 might relate to observed increases in MS incidence.13
Some of the limitations faced by observational studies can be
mitigated through instrumental variable methods, in which
a variable is used as proxy for an exposure to explore the effect
of that exposure on an outcome. In mendelian randomization
(MR), genetic variants are used as instrumental variables to
test for a causal association between a risk factor and an
outcome.14 Because alleles linked with different traits are
randomly assigned at conception, the MR design greatly
limits confounding15 and avoids reverse causation.14 To
assess the effect of age at puberty on MS susceptibil-
ity, we performed a 2-sample MR analysis using genetic
associations from large genome-wide association studies
(GWASs). Here, we first explore whether participants with
genetic variants associated with later age at puberty also
have a lower risk of MS. Second, we use recent develop-
ments in MR methodology to determine whether pubertal
timing exerts direct effects on MS susceptibility independently
of BMI.
Methods
Genetic variants associated with age
at puberty
To select our genetic instruments, we used single-nucleotide
polymorphisms (SNPs) associated with age at menarche from
the largest GWAS meta-analysis to date by the Reproductive
Genetics (ReproGen) consortium,16 combining 329,245
women of European ancestry (table). The effect of these
variants was measured in years. The genetic architecture of
pubertal timing across both sexes is highly correlated (genetic
correlation [rg] = 0.75; p = 1.2 × 10
−79), allowing these
variants to provide insight into pubertal timing in males
as well.16 Indeed, these variants have previously been used
in an MR analysis of prostate cancer risk,16 and the strong
overlap has provided a basis for a combined GWAS of
men and women.17 Therefore, the genetic variants identi-
fied by the ReproGen consortium are hereafter referred
to as being associated with puberty rather than menarche
alone.
For our main MR analysis, we included as candidate genetic
instruments 377 genome-wide significant (p < 5 × 10−8) au-
tosomal variants associated with pubertal timing. In a sensi-
tivity analysis, we restricted the MR analysis to 311 SNPs with
a concordant direction of effect in a GWAS of age at voice
breaking in 54,871 men from 23andMe.16 To ensure that all
selected SNPs are independent, we measured the degree of
linkage disequilibrium between variants and excluded those
with a value of r2 > 0.05 in the European subset of 1,000
Genomes18 using PLINK software version 1.9.19
Genetic variants associated with MS
Corresponding effects of the puberty-associated SNPs on
MS susceptibility were derived from the discovery cohorts
of the latest International Multiple Sclerosis Genetics
Consortium (IMSGC) meta-analysis, which includes up to
41,505 participants (14,802 cases with MS and 26,703
controls).20 Further details on the eligibility criteria, MS
case ascertainment, and demographic characteristics can be
found in the original publication.20 For puberty-associated
variants not directly ascertained in the IMSGC dataset, we
identified proxy SNPs in high linkage disequilibrium (r2 >
0.8) using PLINK and samples of European descent from
1,000 Genomes18 or the UK10K consortium.21 The odds
ratios (ORs) and p values of the summary statistics from the
IMSGC were transformed into β coefficients and standard
errors for subsequent analyses. If the OR was exactly 1
(which occurred for 2 variants), the β coefficient was closely
approximated on the basis of the OR displayed by imme-
diately neighboring SNPs.
For each genetic variant, alleles were aligned and matched so
that their effects correspond to an increase in age at puberty.
The orientation of proxy alleles was based on phasing in-
formation from 1,000 Genomes.18 We examined the datasets
contributing to the genetic estimates for age at puberty and
MS to identify overlapping sets of participants because this
can introduce bias in 2-sample MR.22
Glossary
BMI = body mass index;CI = confidence interval; EGG = Early Growth Genetics; ENGAGE = European Network for Genetic
and Genomic Epidemiology; GWAS = genome-wide association study; HLA = human leukocyte antigen; IMSGC =
International Multiple Sclerosis Genetics Consortium; MR = mendelian randomization; MS = multiple sclerosis; OR = odds
ratio; ReproGen = Reproductive Genetics; SNP = single-nucleotide polymorphism.
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Genetic variants associated with BMI
Pubertal timing and weight status share common regulatory
mechanisms23 and show strong genetic correlation (rg =
−0.35, p = 1.6 × 10−72).16 In general, BMI-increasing alleles
lead to earlier puberty.16 To investigate the effect of pubertal
timing on MS independently of weight status, we accounted
for the effect of puberty-associated SNPs on both adult and
childhood BMI. For adult BMI, we used a densely imputed
GWAS of 87,048 European individuals from the European
Network for Genetic and Genomic Epidemiology (EN-
GAGE) Consortium24 and adjusted for age, age2, and
study-specific covariates. For childhood BMI, sex- and age-
adjusted genetic data for 35,668 children of European
descent were obtained from the Early Growth Genetics
(EGG) consortium.25 Proxy identification and allele
alignment were implemented as described for the MS
susceptibility dataset.
MR analyses
For the main analysis, we applied inverse-variance weighted
2-sample MR26–29 to obtain effect estimates of genetically
predicted pubertal timing on MS susceptibility. In brief, we
weighted the effect of each SNP on MS susceptibility by its
effect on age at puberty using the ratio method.28 We com-
bined the individual effect estimates thus obtained into
a summary measure reflecting the effect of pubertal timing on
MS risk using an inverse-variance weighted random-effects
model. We also measured the degree of heterogeneity across
the individual effect estimates derived from each genetic
variant using the Cochran Q test and I2 statistic. In a sec-
ondary analysis, we repeated this method using the restricted
set of SNPs with directionally concordant effects on age at
menarche and voice breaking.
Next, to account for potential effects of weight status, we
performed a multivariable MR30,31 in which the genetic effects
of the same puberty-associated variants on adult and childhood
BMI were separately included in a weighted regression analysis.
To further explore the effects of weight status, we stratified the
age-at-puberty SNPs into those individually associated with
BMI (p < 0.05 in the ENGAGE or EGG datasets) and those
not associated with BMI. This p value threshold was used to
obtain 2 SNP subsets that differ in the strength of their asso-
ciation with BMI, rather than as a measure of significance. The
association with MS susceptibility was then tested separately
within each of the SNP subsets.
Within the context ofMR studies, pleiotropy denotes a situation
in which genetic variants affect the outcome (MS risk) through
pathways other than the exposure of interest (age at puberty).
Whereas the association of genetic variants with pathways along
the same causal chain as the effect of interest (vertical pleiot-
ropy) does not breach the assumptions of MR, variants asso-
ciated with multiple distinct pathways (horizontal pleiotropy)
can induce bias. We took several steps to investigate the pos-
sibility of horizontal pleiotropy and to reduce its likelihood.
First, we excluded from all analyses variants within human
leukocyte antigen (HLA) genes given the strength of their as-
sociation with MS and the complexity of linkage disequilibrium
at this locus. Second, we inspected funnel plots of the precision
of the association between pubertal timing andMS risk given by
each SNP against the estimate of this association.32 Visual
asymmetry on this plot indicates the presence of directional
pleiotropy, that is, horizontal pleiotropy leading to bias in
a given direction. Third, we applied multivariable MR-Egger
regression to account for the possibility of unmeasured hori-
zontal pleiotropy after accounting for the effects of BMI (adult
and childhood).33 The intercept of this regression allows de-
tection of directional pleiotropy, while the regression coefficient
provides a causal estimate largely robust to horizontal pleiot-
ropy, insofar as the magnitude of a potential pleiotropic effect is
independent of the effects of the genetic variants on pubertal
timing or BMI (described as the InSIDE assumption33,34).
To exclude the possibility of reverse causation, we tested
whether genetically increased risk of MS influences pubertal
timing. Here, we selected non-HLA variants associated with
MS susceptibility in the latest IMSGC meta-analysis20 and
applied an inverse-variance weighted MR with age at puberty
as the outcome using the same methods as above.
All statistical analyses were performed in R (version 3.4.1).
The α level for statistical significance was set to 0.05.
Standard protocol approvals, registrations,
and patient consents
All data sources used in this study (IMSGC, ReproGen,
ENGAGE, and EGG consortia) received approval from
Table Details of datasets included in the MR analyses
Phenotype Consortium Participants (cases with MS), n Source (if publicly available)
MS IMSGC 41,505 (14,802) Not available
Age at menarche ReproGen 329,345 reprogen.org/data_download.html
Adult BMI (age, sex adjusted) ENGAGE 87,048 diagram-consortium.org/2015_ENGAGE_1KG/
Childhood BMI (age, sex adjusted) EGG 35,668 egg-consortium.org/childhood-bmi.html
Abbreviations: BMI = body mass index; EGG = Early Growth Genetics; ENGAGE = European Network for Genetic and Genomic Epidemiology; IMSGC =
International Multiple Sclerosis Genetics Consortium; MR = mendelian randomization; MS = multiple sclerosis; ReproGen = Reproduction Genetics.
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institutional review boards and obtained informed consent
from all participants.16,20,24,25
Data availability
Summary-level data for the genetic associations with age at
puberty, adult BMI, and childhood BMI are publicly available
and can be obtained through the links provided in the table. In
addition, the dataset used to generate the results in the current
study is available from the corresponding author on request.
Results
Selection of genetic instruments
A flow diagram of the SNP selection process is presented in
figure 1. None of the 377 candidate genetic instruments were
in linkage disequilibrium. We excluded a SNP near HLA-
DQB1 (rs3021057) because of its known pleiotropic effects,
leaving 376 SNPs for the subsequent steps. For the genetic
association with MS risk, a total of 345 autosomal non-HLA
variants associated with pubertal timing were directly
ascertained in the IMSGC meta-analysis. For another 27
variants, proxies were identified with a median value of r2 of
1.00 (range 0.83–1.00). Altogether, these 372 SNPs
explained 7.1% of the variance in pubertal timing in an in-
dependent cohort16 and were carried forward for the main
analysis. Of those, 311 SNPs showed directionally concor-
dant effects on age at menarche and voice breaking and were
selected for a secondary analysis (21 proxy SNPs, median r2
= 0.98, range 0.83–1.00). Participant overlap between the
age at puberty and MS risk genetic datasets was negligible,
representing at most 0.13% of the sample size.
For the genetic association with BMI, we undertook a similar
process. For adult BMI, all 372 SNPs associated with age at
puberty included in the main analyses were extracted from the
ENGAGE consortium dataset, either directly (n = 345) or
through a proxy (n = 27, median r2 = 1.00, range 0.83–1.00).
For childhood BMI, only 343 SNPs were present in the EGG
consortium dataset, with 149 identical SNPs and 194 proxies
(median r2 = 0.98, range 0.59–1.00).
MR estimates
Inverse-variance weighted MR analysis revealed that a 1-year
increase in age at puberty was associated with an 8% lower risk
of MS (OR 0.92, 95% confidence interval [CI] 0.86–0.99, p =
0.032) (figure 2). A secondary analysis using the restricted set
of 311 SNPs with directionally concordant effects on age at
menarche and voice breaking resulted in similar findings (OR
0.92, 95% CI 0.86–0.99, p = 0.040). The Cochran Q test and
I2 statistic revealed moderate heterogeneity among the in-
dividual SNP effect estimates in the main analysis (Q = 665.9,
p = 1.1 × 10−16; I2 = 44% [37%–51%]), which decreased only
slightly with the restricted set of SNPs (Q = 506.8, p = 1.1 ×
10−11; I2 = 39% [30%–47%]).
In a multivariable MR analysis, the effect of age at puberty on
MS after accounting for the contribution of adult BMI at-
tenuated (OR 0.96, 95% CI 0.89–1.04, p = 0.36). Repeating
the multivariable analysis after adjusting for the effects of
Figure 1 Flowchart for selection of genetic variants associated with age at puberty
BMI = bodymass index; IMSGC = InternationalMultiple
Sclerosis Genetics Consortium; LD = linkage disequi-
librium;MS =multiple sclerosis; 1KG = 1,000Genomes;
ReproGen = Reproductive Genetics; SNP = single-nu-
cleotide polymorphism.
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childhood BMI yielded similar results (OR 0.97, 95% CI
0.89–1.05, p = 0.40). A univariable inverse-variance weighted
analysis with a set of 115 variants associated with age at pu-
berty and nominally associated with either adult or childhood
BMI resulted in a strong association between age at puberty
and MS susceptibility (OR 0.81, 95% CI 0.70–0.93, p =
0.002). Conversely, the 257 age-at-puberty SNPs that were
not associated with BMI demonstrated a lack of association
(OR 0.99, 95% CI 0.91–1.08, p = 0.829).
The funnel plot was symmetric and therefore not suggestive
of directional pleiotropy (figure 3). Similarly, the multivari-
able MR-Egger regression intercept was estimated to be
centered around zero (intercept −0.002, 95% CI −0.009 to
0.005, p = 0.622), and the estimate from the regression slope
was consistent with the absence of an independent effect of
pubertal timing on MS risk after adjustment for BMI (OR
1.01, 95% CI 0.82–1.24, p = 0.929).
Finally, testing whether MS susceptibility influences age at
puberty with an inverse-variance weighted MR, we found that
genetically increased MS susceptibility was not associated
with age at puberty (OR 0.99 per log-odds increase in MS,
95% CI 0.98–1.01, p = 0.328).
Discussion
Using an MR design in 14,802 cases with MS and 26,703
controls, this study found evidence that genetically predicted
later puberty is associated with a protective effect on MS risk.
Specifically, each 1-year increase in age at puberty conferred
an 8% decrease in odds of MS. After adjustment for
genetically predicted BMI in both adulthood and childhood,
this association was attenuated, and its CIs included the null.
In addition, stratified MR analyses of the puberty-related
variants based on their association with BMI further support
this evidence because puberty-related variants not associated
with BMI had no influence on MS risk, while puberty-related
variants associated with BMI did influence MS risk. This
suggests that effects specific to pubertal timing such as longer
Figure 2 MR estimates of the association between age at puberty and risk of MS
aGenetic association with age at voice breaking derived from a genome-wide association study of 54,871 men from 23andMe.16 BMI = body mass index; CI =
confidence interval; IVW = inverse-variance weighted; MR = mendelian randomization; MS = multiple sclerosis; SNP = single-nucleotide polymorphism.
Figure 3 Funnel plot for the effect of age at puberty on risk
of MS
For each single-nucleotide polymorphism (SNP), the resulting mendelian
randomization (MR) estimate is plotted against the minor allele frequency
(MAF)–corrected association with pubertal timing. Red vertical line repre-
sents the summary measure of the effect of a 1-year increase in age at
puberty on risk of multiple sclerosis (MS) on the log-odds ratio scale. Sym-
metry noted in this plot provides evidence against the presence of di-
rectional horizontal pleiotropy. IVW = inverse-variance weighed.
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duration of exposure to sex hormones do not have large
effects on MS susceptibility. While small effects independent
of BMI cannot be excluded, the relatively narrow CIs do not
support a clinically relevant influence.
The association between pubertal timing and weight status is
complex and plausibly bidirectional. Increased adiposity in
childhood has been linked to earlier pubertal maturation,35
although this relationship may be nonlinear in boys.36 Fur-
thermore, several studies report evidence for an association
between earlier age at puberty and later obesity.9 Therefore,
we sought to control for both genetically predicted adult and
childhood BMI, and we observed a similar magnitude of at-
tenuation in the association between pubertal timing and risk
of MS. However, there is a strong association between
childhood and adult BMI,25,37 which limits the exploration of
age-specific effects. Nonetheless, postpubertal rather than
childhood obesity is most clearly related to MS
susceptibility,38,39 making the association between pubertal
timing and adult obesity the most likely mediator of the effect
of age at puberty on risk of MS. Because it appears that BMI
and pubertal timing are in the same causal biological pathway,
the association of the selected genetic variants with both
exposures represents an example of vertical pleiotropy due to
shared biological underpinnings and thus does not bias the
MR estimates.
Previous observational studies reporting the relevance of
pubertal timing in MS have yielded conflicting results. An
early study observed a lower age at menarche in 118 female
cases with MS compared to an equivalent number of controls
(12.3 vs 12.7 years, p = 0.01).2 A larger case-control study
reproduced this finding in 4,472 female cases with MS and
658 controls (12.4 vs 12.6 years, p = 1.7 × 10−4).3 Consistent
with our findings, the authors found a 10% decrease inMS risk
per 1-year increase in age at puberty.3 No association was seen
in male cases, although the sample size was 4-fold smaller.
Recently, a study using the Danish National Birth Cohort
reported 77,330 women, 226 of whom eventually developed
MS. In this cohort, a 1-year increase in age at puberty trans-
lated in a 13% reduction in MS risk.1 In contrast, other case-
control studies5,7,8,40 did not find an association between age
at puberty and MS susceptibility, while another even reported
a higher age at menarche among female cases.6 However,
most of these discordant studies were limited by small num-
bers and low power.
In addition to these variable results, the contribution of
weight status to the association between pubertal timing
and MS had been little studied. In the study based on the
Danish National Birth Cohort, the authors controlled for
the effect of BMI in their analysis.1 While they observed
little attenuation in the association between age at puberty
and MS in females, BMI was available only at a mean age of
30 years. Because the association with MS seems most ro-
bust for adolescent obesity,38,39 residual mediating effects
by BMI cannot be excluded. In contrast, the MR method in
this study accounted for the lifetime effects of genetic var-
iants on BMI.
While this study does not support substantial direct effects of
pubertal timing on MS independently of weight status, it did
not ascertain its potential role on disease course after onset, as
some studies have suggested.41,42 Furthermore, puberty at-
tainment itself, rather its timing, may still play direct roles in
MS initiation because this transition period relates to im-
portant hormonal and immune changes, as well as brain
maturation.43 For instance, sexual maturity was shown to
enhance CNS autoimmunity in female experimental auto-
immune encephalomyelitis, a murine model for MS.4
A major strength of this study is the MR design, which reduces
confounding15 and contributes to establishing causality. The 2-
sample approach also allowed us to maximize statistical power
by leveraging genetic data from large cohorts, totaling
>450,000 individuals and including 14,802 cases withMS. This
study also has some limitations. First, the use of summary-level
statistics from the IMSGC precluded separate analysis of male
and female cases in the total sample. Second, the possibility of
pleiotropy can be addressed only indirectly, and while com-
bining genetic variants allowed us to achieve adequate power,
some may relate to MS risk through pathways other than
pubertal timing or BMI. However, we undertook several steps
to ensure that this had not biased our results. We excluded
from all analyses the pleiotropic SNP rs3021057 near HLA-
DQB1. In addition, the presence of moderate heterogeneity
between the MR estimates from the inverse-variance weighted
analysis is likely due to the SNPs showing a variable re-
lationship with BMI, in addition to their association with age at
puberty. While heterogeneity can be indicative of horizontal
pleiotropy,44 the association of the SNPs with those 2 phe-
notypes is expected to result in the detection of heterogeneity
on the CochranQ test and I2 statistic.45 Conversely, the funnel
plot and multivariable MR-Egger intercept did not reveal ev-
idence of directional, or unbalanced, pleiotropy. Moreover, the
multivariable MR-Egger regression was consistent with the
finding that age at puberty is related to MS risk through BMI-
related pathways. This method is largely robust to pleiotropic
effects as long as the InSIDE assumption is satisfied.33,34
Consequently, it seems unlikely that genetic pleiotropy can
account for our results. Third, MR studies can be confounded
by population stratification if SNPs are associated with sub-
populations of different ancestry and carrying distinct MS
risks. To avoid this, we included only individuals of European
ancestry and used GWASs that included genomic control.
Lastly, the effect estimates reported in this study assume the
presence of a linear relationship between age at puberty and
MS risk. While nonlinear associations have been reported for
associations between age at puberty and cardiovascular dis-
ease46 and diabetes mellitus,47 a population-based study did
not support this being the case forMS,1 at least in female cases.
This study provides evidence that higher genetically predicted
age at puberty is protective against the development of MS.
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Themagnitude of this association appears to be dependent on
obesity, suggesting that pathways specific to pubertal timing
are less likely to be direct determinants of MS risk. Prevention
strategies should therefore be aimed at decreasing rates of
obesity.
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